Catalent & BASF Join Forces to Solve Bioavailabilty Challenges
Catalent Pharma Solutions and BASF recently announced they have entered into a broad collaboration and Open Alliance to provide solutions to overcome bioavailability challenges of new molecular entities with solubility or permeability challenges.
The companies aim to combine their world-leading expertise to provide pharmaceutical customers with a unique range of seamless solutions to address pipeline challenges with a large majority of BCS Class II and IV poorly bioavailable compounds. From feasibility studies across multiple technologies, solid-state chemistry, consulting and training, expert formulation services, excipients, and optimal dose form development, to scale-up and supply, BASF and Catalent provide a full solution to one of the most important pipeline challenges in the industry, getting better treatments to market faster.
BASF has extensive ingredient formulation and material science expertise, as well as world-class excipient products and has been a leader in developing hot-melt extrusion technology solutions. Catalent is the leading global partner in drug formulation and development as well as in finished oral dose manufacturing, with more than 75 years of experience in providing bioavailability solutions.
“We are very pleased to collaborate with BASF to bring this unique and impactful solution to our customers,” said Ian Muir, President of Catalent’s Modified Release Technologies business unit. “BASF brings significant strengths and expertise that match very well with Catalent’s expertise in offering multiple solutions for poorly soluble compounds; including our Softgel platform and OptiMelt hot-melt extrusion technologies. Our proven track record of developing, scaling up, and manufacturing pharmaceutical products globally also provides for an important seamless integration from development to commercialization and ongoing supply.”
“We are glad to bring our in-depth knowledge of polymeric excipients, including innovations like SOLUPLUS into this open alliance,” added Ralf Fink, VP Global Marketing at BASF Pharma Ingredients & Services business unit. “With our broadest portfolio of solubilizers and excipients for hot-melt extrusion, coupled with Catalent’s strengths in development, formulation, and manufacturing, we are in a unique position to solve the solubility challenge. With this open alliance, we help our customers in the development and commercialization of drugs with poor bioavailability.”
Catalent has made significant investments in OptiMelt hot-melt extrusion and fluid bed lab, pilot, and commercial-scale equipment at its Schorndorf, Germany, facility, OptiMelt hot-melt extrusion at its Somerset, NJ, facility, training and seamless method development to operationalize this open alliance. BASF is continuously investing in new excipients to provide advanced solutions for the pharmaceutical industry.
From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings, and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs approximately 9,400 people at 29 facilities worldwide and in fiscal year 2011 generated more than $1.6 billion in annual revenue. Catalent is headquartered in
BASF is the world’s leading chemical company: The Chemical Company. Its portfolio ranges from chemicals, plastics, performance products and crop protection products to oil and gas. It combines economic success, social responsibility, and environmental protection. Through science and innovation BASF enables customers in almost all industries to meet the current and future needs of society. Further information on BASF is available at www.basf.com or www.pharma-ingredients.basf.com.
Total Page Views: 1296
